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ess: dozol@hotmail.comSummary Patients with pleural infections have a high risk of morbidity and
mortality with prolonged hospitalization. The best methods for treating pleural
infections remain debatable. Although the increasing drainage volume effect of
streptokinase adjunctive to chest-tube, is well known, its effect on clinical
outcomes like duration of hospitalization and need for further surgery, remains
controversial.
The aim of this study was to analyze the etiological and microbiological factors
for pleural infections, and assess the effect of streptokinase adjunctive to chest tube
for clinical outcomes.
Charts of patients with a chest disease department discharge diagnosis of
complicated parapneumonic effusion or empyema were retrospectively reviewed. Of
the 107 patients (85 male), the mean age was 47.9717.1 years. The most frequently
shown bacteriological agent was Staphylococcus aureus. Drainage with thoracentesis
was used in 44 patients (group 1); chest tube was performed in 44 patients (group 2)
and intrapleural streptokinase was given after chest tube insertion in 19 patients
(group 3). Mean hospitalization time in group 1 was shorter than the other two
groups (Po0:05), but there was no significant difference betweens group 2 and 3.
Our mortality rate was 8.4%. Success rates were 95.4%, 65.9% and 78.5% in groups 1,
2, and 3, respectively (P40:05).
Intrapleural streptokinase is a safe procedure but it did not effect the duration of
hospitalization, mortality and success rate. Mortality remains especially high in
patients with concomitant disease.
& 2005 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserve
4272996.
(D. Ozol).Introduction
The pleural involvement associated with bacterial
infections includes simple parapneumonic effusionsd.
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early diagnosis and antibiotic therapy of pneumo-
nia, in most cases the course of the disease is
uncomplicated, and the simple PPE resolves with
antibiotic therapy. However, in 5–10% of the
patients, PPE becomes more complicated and leads
to empyema.1 There were three stages of empye-
ma, namely the exudative, fibrinopurulent and
organizing phases. In the first stage, exudative
fluid becomes infected and as infection progresses,
fluid becomes thick and purulent with fibrin, white
blood cells and organisms. With the organization of
fibroblasts; loculations developed and the organiz-
ing phase occurs.2
Empyema is one of the oldest of diseases and it
is still associated with considerable morbidity
and high mortality rate up to 20%.3 The main
therapy for pleural infection that was known
since Hippocrates is effective drainage of the
pleural collection. Drainage can be done by
repeated thoracentesis, image-guided catheter,
closed chest tube drainage with or without fibrino-
lytic therapy, thorocoscopic drainage and open
thorocotomy with decortications and rib resec-
tions.4 Early video-assisted thoracoscopic surgery
(VATS) has shown promising results5,6 but its routine
use is out of reach for most of the hospitals in
the world and so far VATS is performed under
general anaesthetic and one lung ventilation.
Furthermore, although surgical procedures achieve
the best drainage, they carry an obvious operative
risk, cost and morbidity. So the best methods for
treating complicated PPE and empyema remain
debatable.
The transition from the exudative to fibrinopuru-
lent phase is not always very clear cut. If there
is too much loculations by fibrinous strands,
fibrinolytic therapy may be considered. Streptoki-
nase and urokinase are the drugs that were used
to resolve the fibrin bands and helps for pleural
drainage. In the past several years, there have
been several studies on the use of fibrinolytics
for loculated pleural infections.7–9 In most of the
studies, drainage volume is the most common
principal end point, but it has been shown that
radiologic change does not predict outcome
and long-term survival.10 The effect of streptoki-
nase on clinical outcomes like duration of hospita-
lization and need for further surgery, remains
controversial.
The aim of this study was to analyze the
etiological and microbiological factors for pleural
infections, and compare the treatment methods,
especially chest tube drainage with or without
intrapleural streptokinase for the duration of
hospitalization, mortality and success rate.Methods
Subjects
We retrospectively analyzed the medical records of
patients with pleural infection treated in our
pulmonology department of a university hospital,
for a 5-year period. Case records were selected
through a computerized search of diagnosis codified
either empyema or complicated PPE at hospital
discharge. The definite diagnosis of complicated
PPE was established by medical history with
classical physical findings in addition to chest
X-ray findings and the presence of two of the
following; pHo7.20, lactate dehydroenase
(LDH)41000 IU/L, or glucose o40mg/dL. Empye-
ma was considered as pus-like thick purulent
pleural fluid obtained by thoracentesis, or positive
pleural fluid gramstain and culture. Thirty-eight
patients with complicated PPE and 69 patients with
empyema were included in the study.Data collection
The following data were collected for each patient:
age, sex, predisposing factors, concomitant dis-
eases, pathogens isolated from cultures of the
pleural effusion, duration of hospitalization, treat-
ment methods including intrapleural fibrinolytic
therapy, mortality and need for further surgical
procedures. The mean duration of empyema
symptoms like cough, fever and chest pain, prior
to treatment, the mean white blood cell count and
pleural pH and LDH prior to treatment were also
noted.
Evaluation of the etiopathogenesis of each
patient’s disease was based on the history and
clinical picture described in the medical records. A
patient was considered to have pneumonia prior to
the development of empyema if there was radio-
graphic evidence of parenchymal infiltrate with
fever and purulent sputum. Thorax computerized
tomography was performed in 38 patients to see
the lung parenchyma and pleural fluid better and
also for the differential diagnosis of obstructive
pneumonia-like malignancy.
In all patients, pleural fluid was collected under
sterile conditions and samples were sent to the
laboratory immediately. But only 72 specimens
were cultured for both aerobic and anaerobic
bacteria. Intravenous antibiotic treatment was
commenced empirically with a second-generation
cephalosporin and clindamycin and then if neces-
sary the antibiotics were changed according to the
microbiologic results when available.
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Table 1 Concomitant diseases.
Concomitant disease n (%)
COPD 20 (18.7)
Diabetes mellitus 15 (14)
CHF 11(10.3)
Malignancy 9 (8.4)
CRF 4 (3.7)
Collagen vascular disease 3 (2.8)
None 45 (42.1)
COPD ¼ chronic obstructive pulmonary disease,
CHF ¼ chronic heart failure, CRF ¼ chronic renal failure.
D. Ozol et al.288Treatment modalities
According to the records, three treatment mod-
alities were found and patients were divided in to
three groups. In group 1, therapeutic thoracentesis
was used. In group 2, 28F to 32F intercostal chest
tube attached to water was inserted. And in
group 3, streptokinase was given from the chest
tube.
If there had been no significant clinical improve-
ment to treatment protocols, thoracoscopic or
open surgical drainage and decortications was
performed. The treatment protocols were analyzed
for duration of hospitalization, mortality, and
success rate. Success rate was defined as resolution
of symptoms and signs of infection with complete
drainage of fluid and discharged from the hospital
without empyema tubes in place and no need for
further surgical intervention.
Each time 250.000 IU dose of streptokinase was
given through the chest tube and was left in the
pleura for 4 h with the chest tube clamped and then
released into underwater seal for drainage. The
chest tubes were removed when the daily drainage
had fallen below 50ml with clinical and radiological
resolution of pleural collection. Streptokinase was
given for 3 times in 6 patients and 2 times in 8
patients. The total number of doses was determined
by patient response. Complications of streptokinase
were also noted as allergy and hemorrhage.
Statistics
Data were reported as mean7SD. Continuous
variables were compared with paired and unpaired
Student’s t-test where appropriate while the w2
test was used to test for differences between
proportions. For the comparison of outcomes of the
groups, Kruskal–Wallis test and Mann–Whitney U
test with bonferroni correction were used. And a P
value o0.05 was considered to be statistically
significant. A software program (SPSS-11) was used
for the analysis.Results
Predisposing factors and concomitant
diseases
There were 107 patients (85 male) with a mean age
of 47.9717.1 years, range between 21 and 76
years. Direct extension of pulmonary parenchymal
infections into the pleural space causes empyema
in 73 (68.2%) patients, postoperative empyema(cholecystectomi for 8 patients, 4 patients had
operated for nephrolityasis) was observed in 12
(11.2%) cases, and history of trauma was present in
2 (1.9%) cases. In the remaining 20 (18.7%) patients
no predisposing factors were identified.
There was a concomitant disease in addition to
empyema in 62 (57.9%) cases, chronic obstructive
lung disease and diabetes mellitus were the 2 most
frequent concomitant diseases (Table 1).
Microbiology and characteristics of pleural
fluid
Forty-two patients (39.2%) were taking antibiotics
before admission to the hospital. A causative agent
could be isolated from the pleural fluid in 40 cases
and from the blood cultures in 9 cases. The most
frequently shown bacteriological agent was
Staphylococcus aureus in 22 cases. We could not
find any relation between concomitant disease and
causative agents (P40:05) (Table 2).
The mean duration of empyema symptoms like
cough and chest pain, prior to treatment was
6.172.3 days. The mean white blood cell count
prior to treatment was 17.272.8 103 cells/mm3.
The mean pleural fluid LDH and pH levels were
2007.37666.7 (IU/L) and 6.670.3, respectively.
There were no significant differences between the
treatment groups in age, sex ratio, frequency of
comorbidity, severity of peripheral leukocytosis and
pleural fluid LDH. But when we compare the mean
duration of empyema symptoms prior to treatment,
and pleural fluid pH for the 3 groups, we found that
there was no significant difference between groups
2 and 3 but in group 1 these parameters were
significantly less than the others (Table 3).
Pleural fluid drainage
During their hospital stay, all patients received a
combination of antibiotics covering both aerobic
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Table 2 Organism isolated from patients with pleural infection according to concomitant disease.
All cases (107), n (%) COPD (20), n (%) DM (15), n (%) Malignancy (9), n (%)
Staphylococcus aureus 22 (20.6) 4 (20) 8 (53.3) 2 (22.2)
Streptococcus pneumonia 13 (12.1) 3 (15) 2 (13.3)
Anaerobe (total) 21 (19.6) 6 (5.6) 4 (3.7) 3 (33.4)
Streptococcus milleria 8 (7.5) 1 (0.9) 2 (1.9) 1 (0.9)
Fusobacterium nucleatum 7 (6.5) 3 (2.8) 1 (0.9) 1 (0.9)
Bacteriodes vulgatus 4 (3.7) 2 (1.9) 1 (0.9) —
Peptostreptococcus 2 (1.9) — — 1 (0.9)
Klebsiella pneumoniae 9 (8.4)
Pseudomonas aeroginosae 5 ( 4.7) 2 (10) 1(6.7) 2 (22.2)
Escherichia coli 4 (3.7) 1 (5)
Streptococcus viridans 4 (3.7) 1 (5)
Not Known 37 (34.6) 7 (35) 1 (6.7) 2 (22.2)
Table 3 Patients and pleural fluid characteristics.
Patients characteristics Group 1 Group 2 Group 3
Age (yr) 46.3712.1 48.2716.5 48.1717.9
Female/male (n) 9/35 10/34 3/16
Concomitant disease (%) 61.3 59.1 56.6
Duration of empyema symptoms (days) 4.971.8* 6.772.4 7.472.3
Blood WBC count ( 106/L) 16.371.9 17.572.2 17.173.1
Pleural fluid LDH (IU/L) 18187458 20927733 22467816
Pleural fluid pH 6.870.2* 6.570.4 6.470.3
Values given as mean7SD, LDH: lactate dehydorogenase level, WBC: white blood cell.
*Po0:05, patients in group 1 versus the other two groups.
107 patients 
44 
 thoracenthesis 
2 died 
sucess rate 95.4 % 
44  
tube drainage 
7 died          8 surgery 
    success rate 65.9 % 
19
tube drainage and streptokinase
4 surgery
success rate 78.5 %
Figure 1 Mortality and need for further surgery accord-
ing to the treatment modalities.
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treated with therapeutic thoracentesis (group 1),
44 patients were treated by chest tube alone
(group 2) and 19 patients were treated with chest
tube and streptokinase (group 3). No complication
was observed in group 3.
Twelve patients, who did not result in complete
resolution of pleural effusion radiologically with
chest tube, were referred to thoracic surgery
division. Nine patients died during therapy. Three
died because of severe pneumonia and sepsis, 6died because of multi-organ insufficiency due to
malignancy. These patients were at prohibitively
high risk of general anesthesia so no further surgical
procedures were applied. Success rates were
95.4%, 65.9% and 78.5% in groups 1, 2 and 3,
respectively (Fig. 1).
Hospitalization time
Mean hospitalization time for all patients was
18.6713.2 days and for groups 1, 2, 3, respec-
tively, 14.8710.1, 21.8715.2 and 20.2713.7 days.
Mean hospitalization time of patients with re-
peated thoracentesis was shorter than the other
two groups (Po0:05). But there was no significant
difference between groups 2 and 3. (Fig. 2).Discussion
We found that mortality remains high especially in
patients with serious concomitant disease, for
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Figure 2 Mean hospitalization time.
D. Ozol et al.290complicated PPE and empyema. Also, intrapleural
streptokinase is a safe procedure but it did not
effect the duration of hospitalization, mortality
and success rate.
The mortality rate among empyema changes
between 5.4% and 22%.2,11 Our mortality rate is
8.4%. Mortality-related prognostic factors were
found as age, causative bacteriological agents like
Streptococcus milleri, concomitant disease and
history of operation.12,13 In our study, we found
that 6 out of 9 patients with malignancy died. So
the main prognostic factor for our study was the
associated concomitant disease. Furthermore,
there was a lower mortality rate in the streptoki-
nase group compared to the drain group but this
was statistically insignificant.
The emergence of antibiotic resistant organisms
and increase in the frequency of nosocomial
infections makes the empirical antibiotic therapy
more important. As sometimes empyema develops
or is recognized after the patient has already
received antibiotics, culture and Gram stain may be
falsely negative in this situation. Reports of
anaerobic bacteria isolated from pleural fluid have
ranged from 38% to76%.14,15 Gram-positive cocci
are the most frequently isolated organisms and the
culture results are often polymicrobial consisting of
anaerobic bacteria.16 According to the microbiolo-
gical aspect, this study has some limitations. We
did not have anaerobic cultures in 1/3rd of the
patients. Furthermore, 39.2% of the patients were
taking antibiotics before admission to the hospital.
So the rate of isolating a causative agent was quite
low. When we compare our results with previous
research that was done in our clinic,17 we found a
trend towards increasing numbers of Staphylococ-
cus aureus infections, similar to the report of
Alfageme et al.18The therapy for empyema thoracic is determined
by the stage. In the early exudative phase of
empyema, repeated drainage may provide ade-
quate drainage, during the fibropurulant phase as
thoracentesis is always unsatisfactory; closed chest
tube drainage is often necessary. Mandal et al.4
used thoracentesis as the primary procedure in 20
cases out of 179 primary empyema patients with a
cure rate of 90%. Our cure rate in thoracentesis
group was 95.4%. Those were the patients in the
early stage of the illness as the prediagnosis
symptom duration was short and also the pleural
fluid pH level was less than the other groups. In the
patients who were in the initial phase of empyema,
thoracentesis can be used as a primary procedure
with close follow up.
It is evident from the studies that streptokinase
and urokinase decrease empyema viscosity, allow
drainage more easily and improve radiological
findings.19,20 However, such surrogate markers do
not necessarily correlate with clinical improve-
ment. Chin and Lim21 showed that thrombolytic
therapy increased the volume of fluid drained from
pleural empyema but did not markedly reduce
morbidity and mortality. Davies et al.22 found that
the reduction in the largest linear dimension of the
pleural fluid collection was greater in the regimen
of the 3-day streptokinase group when compared
with the control group, but the duration of the
hospital stay and the time to normalization of the
total white blood cell count and temperature were
found similar for both groups.
In our study, the rate of further surgical
procedure was 11.2% and the mean duration of
hospitalization was similar in groups 2 and 3. We
failed to demonstrate any effect of streptokinase
on duration of hospitalization and need for further
surgery. Results of small studies have been mixed:
Both Lim and Chin23 and Davies et al.22 found that
streptokinase had no effect on length of hospitali-
zation and mortality when compared to drainage
with chest tube alone while both Diacon et al.24
and Bouros et al.25 concluded that intrapleural
streptokinase adjunctive to chest tube drainage
improved the clinical treatment success.
The duration of hospital stay is determined by
both patient and management factors. It is im-
portant for a patient to apply to the hospital early
as we found that the duration of hospital stay was
short in patients whose prediagnosed symptom
duration were also short. As empyema patients
are heterogeneous in their bacteriology, the phase
of empyema and associated concomitant diseases,
multicenter studies with a well-defined classifica-
tion of patients are needed to evaluate the best
therapy for empyema and complicated PPE.
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